Overview
My primary research interest is in conduct and methodology of large randomized clinical trials in heart disease. I have led a number of large international clinical studies in heart attacks, unstable angina, heart failure, and atrial fibrillation. I have lead clinical studies of blood thinners and coronary intervention for heart attacks, stroke prevention in atrial fibrillation, and prevention of heart attack for patients with coronary artery disease. I have been co-director of the Reperfusion of Acute MI in Carolina Emergency Departments (RACE) project that is a North Carolina state-wide program to improve reperfusion care for acute myocardial infarction. I serve as the Chairman of the American Heart Association Mission: Lifeline program to improve heart attack care nationally as well as the American College of Cardiology/American Heart Association guideline committee for heart attack care. I have also studied the effects of genetic variation on heart disease. I work with the National Institute of Health and the Federal Drug Administration on evaluation of heart disease and of new drugs. I have developed tools to predict which patients are at risk for death, heart attack, and need for hospitalization.
Current Appointments & Affiliations
Fred Cobb, M.D. Distinguished Professor of Medicine
·
2024 - Present
Medicine, Cardiology,
Medicine
Professor of Medicine
·
2007 - Present
Medicine, Cardiology,
Medicine
Professor in the School of Nursing
·
2015 - Present
School of Nursing
Member in the Duke Clinical Research Institute
·
1988 - Present
Duke Clinical Research Institute,
Institutes and Centers
Recent Publications
Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.
Journal Article Am Heart J · April 2025 BACKGROUND: SGLT-2i and GLP-1RA are recommended for persons with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD); for those prescribed, little is known about reasons for discontinuation. METHODS: From the COORDINATE-Diabetes randomized t ... Full text Link to item CiteBiomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation.
Journal Article J Am Coll Cardiol · March 25, 2025 BACKGROUND: In patients with atrial fibrillation (AF) the risk of ischemic stroke is central to recommendations for stroke-prevention treatment. OBJECTIVES: The authors evaluated the biomarker-based Age, Biomarkers, Clinical history (ABC)-AF-stroke risk sc ... Full text Link to item CiteApixaban Dose in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Journal Article JACC Adv · March 20, 2025 BACKGROUND: Studies have demonstrated the safety and efficacy of reducing the dose of apixaban from 5.0 mg to 2.5 mg twice daily in patients with atrial fibrillation (AF) and ≥2 dose-reduction criteria (age ≥80 years, body weight ≤60 kg, serum creatinine ≥ ... Full text Link to item CiteRecent Grants
Stimulating Access to Research in Residency (StARR) - NHLBI
Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 2018 - 2028CCC: The Regional Approaches to Cardiovascular Emergencies- Cardiac ARreSt (RACE-CARS) Cluster-Randomized Trial 1/2
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2027Integrated Biostatistical Training for CVD Research
Inst. Training Prgm or CMEMentor · Awarded by North Carolina State University · 2022 - 2027View All Grants
Education, Training & Certifications
University of Connecticut ·
1984
M.D.